208 related articles for article (PubMed ID: 8413955)
1. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
Fowler JS; Volkow ND; Logan J; Schlyer DJ; MacGregor RR; Wang GJ; Wolf AP; Pappas N; Alexoff D; Shea C
Neurology; 1993 Oct; 43(10):1984-92. PubMed ID: 8413955
[TBL] [Abstract][Full Text] [Related]
2. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.
Bench CJ; Price GW; Lammertsma AA; Cremer JC; Luthra SK; Turton D; Dolan RJ; Kettler R; Dingemanse J; Da Prada M
Eur J Clin Pharmacol; 1991; 40(2):169-73. PubMed ID: 1906004
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase B inhibitor, selegiline, reduces
Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P
Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327
[TBL] [Abstract][Full Text] [Related]
4. Measurement of cerebral monoamine oxidase B activity using L-[11C]deprenyl and dynamic positron emission tomography.
Lammertsma AA; Bench CJ; Price GW; Cremer JE; Luthra SK; Turton D; Wood ND; Frackowiak RS
J Cereb Blood Flow Metab; 1991 Jul; 11(4):545-56. PubMed ID: 1904879
[TBL] [Abstract][Full Text] [Related]
5. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition.
Fowler JS; Volkow ND; Wang GJ; Pappas N; Logan J; MacGregor R; Alexoff D; Wolf AP; Warner D; Cilento R; Zezulkova I
J Addict Dis; 1998; 17(1):23-34. PubMed ID: 9549600
[TBL] [Abstract][Full Text] [Related]
6. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
Freedman NM; Mishani E; Krausz Y; Weininger J; Lester H; Blaugrund E; Ehrlich D; Chisin R
J Nucl Med; 2005 Oct; 46(10):1618-24. PubMed ID: 16204711
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide.
LeWitt PA; Segel SA; Mistura KL; Schork MA
Clin Neuropharmacol; 1993 Aug; 16(4):332-7. PubMed ID: 8374913
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
9. Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: imaging in volunteers and patients with temporal lobe epilepsy.
Buck A; Frey LD; Bläuenstein P; Krämer G; Siegel A; Weber B; Schubiger PA; Wieser HG
Eur J Nucl Med; 1998 May; 25(5):464-70. PubMed ID: 9575241
[TBL] [Abstract][Full Text] [Related]
10. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
Gulyás B; Pavlova E; Kása P; Gulya K; Bakota L; Várszegi S; Keller E; Horváth MC; Nag S; Hermecz I; Magyar K; Halldin C
Neurochem Int; 2011 Jan; 58(1):60-8. PubMed ID: 21075154
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase B inhibitors for early Parkinson's disease.
Macleod AD; Counsell CE; Ives N; Stowe R
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
[TBL] [Abstract][Full Text] [Related]
12. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.
Henriot S; Kuhn C; Kettler R; Da Prada M
J Neural Transm Suppl; 1994; 41():321-5. PubMed ID: 7931245
[TBL] [Abstract][Full Text] [Related]
13. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
15. Turnover of monoamine oxidase B (MAO-B) in pig brain by positron emission tomography using 11C-L-deprenyl.
Oreland L; Jossan SS; Hartvig P; Aquilonius SM; Långström B
J Neural Transm Suppl; 1990; 32():55-9. PubMed ID: 2128512
[TBL] [Abstract][Full Text] [Related]
16. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping.
Fowler JS; Wang GJ; Logan J; Xie S; Volkow ND; MacGregor RR; Schlyer DJ; Pappas N; Alexoff DL; Patlak C
J Nucl Med; 1995 Jul; 36(7):1255-62. PubMed ID: 7790952
[TBL] [Abstract][Full Text] [Related]
17. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.
Fowler JS; Volkow ND; Logan J; Wang GJ; MacGregor RR; Schyler D; Wolf AP; Pappas N; Alexoff D; Shea C
Synapse; 1994 Oct; 18(2):86-93. PubMed ID: 7839316
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of monoamine oxidase B in peripheral organs in humans.
Fowler JS; Logan J; Wang GJ; Volkow ND; Zhu W; Franceschi D; Pappas N; Ferrieri R; Shea C; Garza V; Xu Y; MacGregor RR; Schlyer D; Gatley SJ; Ding YS; Alexoff D
J Nucl Med; 2002 Oct; 43(10):1331-8. PubMed ID: 12368371
[TBL] [Abstract][Full Text] [Related]
19. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
Hirvonen J; Kailajärvi M; Haltia T; Koskimies S; Någren K; Virsu P; Oikonen V; Sipilä H; Ruokoniemi P; Virtanen K; Scheinin M; Rinne JO
Clin Pharmacol Ther; 2009 May; 85(5):506-12. PubMed ID: 19129751
[TBL] [Abstract][Full Text] [Related]
20. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
Fowler JS; Logan J; Volkow ND; Shumay E; McCall-Perez F; Jayne M; Wang GJ; Alexoff DL; Apelskog-Torres K; Hubbard B; Carter P; King P; Fahn S; Gilmor M; Telang F; Shea C; Xu Y; Muench L
Neuropsychopharmacology; 2015 Feb; 40(3):650-7. PubMed ID: 25249059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
